Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,315 full-time employees. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Mr. Ming Hsieh est le Chairman of the Board de Fulgent Genetics Inc, il a rejoint l'entreprise depuis 2016.
Quelle est la performance du prix de l'action FLGT ?
Le prix actuel de FLGT est de $15.82, il a 下降 de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Fulgent Genetics Inc ?
Fulgent Genetics Inc appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de Fulgent Genetics Inc ?
La capitalisation boursière actuelle de Fulgent Genetics Inc est de $470.6M
Est-ce que Fulgent Genetics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 4 analystes ont établi des notations d'analystes pour Fulgent Genetics Inc, y compris 2 achat fort, 5 achat, 2 maintien, 0 vente et 2 vente forte